Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (29437)	5/12/1999 9:02:00 AM
From: Doug R	Respond to of 79260

Alright Allan, I'll have to jump in on this news thing... Bioject Medical Technologies Inc. (Nasdaq: BJCT), the leading manufacturer of jet injection devices for needle-free drug delivery and developer of an ambulatory, continuous blood glucose monitoring system, announced today that the Biojector(R) 2000 jet injector is being tested in a Phase I human trial to deliver a malaria DNA vaccine made by Vical Incorporated (Nasdaq: VICL) (San Diego, CA). The study is being conducted under the direction of principal investigators LCDR Judy Epstein, MC, USNR, and CAPT Stephen L. Hoffman, MC, USNR, from the Malaria Program, Naval Medical Research Center, Bethesda, MD. The clinical trial center where the study is being conducted is the U.S. Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD and the work is supported by the Office of Naval Research's Advanced Technology Development Program and the Department of Defense Military Infectious Diseases Research Program. "Malaria parasites infect 200 to 300 million people worldwide annually, causing two to three million deaths per year; thus development of an effective vaccine is of paramount importance," said, CAPT Hoffman, Director of the Navy Malaria Program. "We hope that use of the Biojector will contribute to the potential efficacy of this DNA vaccine." "Bioject is committed to developing new applications for our portfolio of needle-free jet injection systems," said Jim O'Shea, Bioject's chairman, president and CEO. "Delivery of DNA vaccines is an area we have been focused on for some time and we are pleased that our needle-free technology is being tested in the delivery of a DNA-based vaccine for the prevention of malaria, a serious, globally widespread disease with no currently available vaccine."